2025年最常用体重管理药物Zepbound(Tirzepatide)现已推出多剂量Kwikpen注射笔

美股速递
Feb 23

礼来公司旗下备受瞩目的体重管理药物Zepbound(Tirzepatide)——这款被预测为2025年处方量最大的减肥疗法,现已正式推出多剂量Kwikpen注射笔剂型。这一新式给药装置将极大提升患者用药的便捷性与精确度,有望进一步巩固该药物在代谢疾病治疗领域的领先地位。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10